NCT00081536Unknown1 期
A Phase I/II Study of Aroplatin and Capecitabine in Subjects With Unresectable Local Recurrence or Distant Metastases of Colorectal Cancer Refractory to 5-FU/Leucovorin and Irinotecan
适应症
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 105
研究概览
简要总结
This study is a Phase I/II study. In Phase I of this study, the objective is to determine the maximum tolerated dose (MTD) of combination therapy with Aroplatin and capecitabine in subjects with unresectable, local recurrence or distant metastases of colorectal cancer refractory to 5-FU/leucovorin and irinotecan. In Phase II, the primary objective is to evaluate the response proportion and duration with Aroplatin/capecitabine therapy. Secondary objectives are to evaluate frequency and severity of adverse events.
详细描述
Phase I Primary Objective:
- Determine the MTD of Aroplatin/capecitabine subjects with unresectable local recurrence or distant metastases of colorectal cancer refractory to 5-FU/LV and irinotecan.
Phase II Primary Objective:
- Evaluate the response proportion and duration with Aroplatin/capecitabine therapy.
Phase II Secondary Objective:
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed colorectal cancer: unresectable local recurrence or distant metastases;
- •Measurable disease (RECIST criteria);
- •Refractory to 5-FU / leucovorin and irinotecan as described below;
- •No prior therapy with oxaliplatin, any other platinum or capecitabine;
- •ECOG score 0-2 (Karnofsky 100-70%);
- •Life expectancy of greater then or equal to 5 months;
- •Adequate hematopoietic, liver and renal function;
- •Women of child-bearing potential have to practice adequate contraception;
- •Signed written informed consent;
- •Subjects must be willing to be followed during the course of treatment/observation and follow-up.
- •Refractory metastatic colorectal cancer
- •The following subjects are regarded refractory to treatment:
- •Those with progression while receiving 5-FU/LV/irinotecan;
- •Those with progression on irinotecan after prior 5-FU/LV treatment;
- •Progression within six months of adjuvant 5-FU/LV/irinotecan;
- •Progression within six months of adjuvant 5-FU/LV followed by progression on irinotecan
- •Subjects must have received at least one or more commonly used 5-FU/leucovorin and irinotecan regimens. Prior adjuvant therapy is allowed including 5-FU/leucovorin or other fluoropyrimidines except capecitabine and irinotecan.
排除标准
- •Previously diagnosed brain metastases if symptomatic and requiring active therapy;
- •Other cancers within the last five years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin;
- •Concurrent chemotherapy or immunotherapy;
- •Prior therapy for colorectal cancer within one month of admission to the present study;
- •Primary or secondary immunodeficiency or use of corticosteroids or other immunosuppressive medication;
- •Any serious concomitant medical or mental illness requiring intense therapy and interfering with participation in this study;
- •Women must not be pregnant or breast-feeding;
- •No participation in any clinical trial involving investigational drugs within 1 month from enrollment into the present study.
研究者
相似试验
Unknown
1 期
Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard TherapiesPancreatic NeoplasmsNCT00081549Aronex Pharmaceuticals111
已完成
1 期
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal CancerRectal CancerSolid TumorColorectal CancerColon CancerNCT02861300David Bajor, MD50
已完成
1 期
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological CancerRecurrent Fallopian Tube CancerLeydig Cell TumorOvarian SarcomaOvarian Stromal CancerRecurrent Cervical CancerRecurrent Endometrial CarcinomaPseudomyxoma PeritoneiRecurrent Ovarian Epithelial CancerRecurrent Ovarian Germ Cell TumorRecurrent Primary Peritoneal Cavity CancerRecurrent Uterine SarcomaRecurrent Vaginal CancerRecurrent Vulvar CancerNCT01652794Case Comprehensive Cancer Center12
Unknown
1 期
A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal CancerMetastatic CancerColorectal AdenocarcinomaColorectal CancerNCT04380103Chinese Academy of Medical Sciences106
已完成
2 期
END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal DoxorubicinEndometrial CancerNCT00401635National Cancer Institute, Naples42